知镜 Cognispect · 医学文献与研究工作台

Why Metrics Matter in Thyroid Eye Disease: An Innovate TED Initiative.

Kazim M, Baldeshi L, Cruz AA, Dolman PJ, Dosiou C, Eckstein A, Kikkawa D, Kossler AL, Mawn LA, Singh Ospina N, Perros P, Rootman DB, Salvi M, Stan MN, Sullivan TJ, Wester ST.
JAMA ophthalmology · 2026-10-01 · PMID 42720935

文献摘要

Importance Advances in the understanding of the pathophysiology of thyroid eye disease (TED) provide an opportunity to use novel, targeted therapeutic agents. However, our capacity to assess the efficacy and indications for the new agents is potentially limited by the clinical metrics used in recent research trials, which fail to adequately capture the clinical complexity and diversity of TED. Objectives To review the features of TED that make it atypical among autoimmune diseases, review the limitations of the currently available metrics, and introduce the Innovate TED Initiative to develop new outcome metrics. Conclusions and relevance To best evaluate and use potential new therapeutic agents for TED, physicians with expertise in the field perceive the need for a novel set of metrics. The outlined Innovate TED Initiative can, through the design and execution of prospective validation studies, develop the requisite metrics for the mutual benefit of physicians, regulatory bodies, the pharmaceutical industry, and patients with TED.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。